Amgen (AMGN) Announces Vectibix Phase 3 Met Primary Endpoint in Exon 2 mCRC
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
